8-K: ADC Therapeutics Updates ZYNLONTA & Pipeline Progress

ADC Therapeutics SA released an updated corporate presentation detailing strong clinical data for ZYNLONTA in lymphoma and outlining a cash runway into 2028.

Summary

• ADC Therapeutics is a commercial-stage pioneer in Antibody-Drug Conjugates (ADCs) with specialized capabilities from clinical development through commercialization.
• The company is focused on expanding its FDA-approved ZYNLONTA (loncastuximab tesirine) into earlier lines of therapy and new indications, while advancing a PSMA-targeting ADC candidate.
• ZYNLONTA is currently approved as monotherapy for adult patients with relapsed or refractory large B-cell lymphoma (r/r DLBCL) after two or more lines of systemic therapy, demonstrating a 48.3% Overall Response Rate (ORR) and 24.8% Complete Response (CR) with a median time to CR of 1.5 months.
• The LOTIS-5 Phase 3 confirmatory trial of ZYNLONTA with rituximab in 2L+ DLBCL has completed enrollment in 2024, with topline data expected in 1H 2026.
• Initial data from the LOTIS-5 safety run-in showed an 80% ORR and 50% CR.
• The LOTIS-7 Phase 1b trial combining ZYNLONTA with glofitamab in r/r Large B-Cell Lymphoma (LBCL) reported an 86.7% CR rate (N=30) as of April 14, 2025, with a manageable safety profile.
• University of Miami investigator-initiated trials (IITs) showed promising results for ZYNLONTA: 69.2% CR rate in r/r Marginal Zone Lymphoma (MZL) (N=26) and 76.9% CR rate for ZYNLONTA with rituximab in r/r Follicular Lymphoma (FL) (N=39).
• The company expects a cash runway into 2028, supported by its strategic plan.
• ADC Therapeutics is advancing IND-enabling activities for a next-generation PSMA-targeting ADC candidate with a novel exatecan-based payload and is seeking research collaborations.

Sentiment

Score: 8

Explanation: The filing presents strong positive clinical data across multiple lymphoma indications for ZYNLONTA, indicating significant market expansion potential and competitive efficacy against established therapies. The projected cash runway into 2028 provides financial stability. While risks inherent to biotech development and commercialization are present, the overall outlook is highly favorable based on the presented data.

Positives

• ZYNLONTA demonstrates rapid, deep, and durable efficacy in 3L+ r/r DLBCL with a 48.3% ORR and 24.8% CR, and a median duration of response not yet reached for CR patients at 2-year follow-up.
• The safety profile of ZYNLONTA is manageable, with no Cytokine Release Syndrome (CRS) or Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS) and no cumulative irreversible toxicities.
• LOTIS-7 (ZYNLONTA + glofitamab) shows a high 86.7% CR rate in r/r LBCL, potentially rivaling CAR T-cell therapy with improved accessibility and a manageable toxicity profile.
• University of Miami IITs for ZYNLONTA in r/r MZL and ZYNLONTA + rituximab in r/r FL reported high CR rates of 69.2% and 76.9% respectively, indicating significant expansion potential.
• The company projects a substantial U.S. peak revenue potential for ZYNLONTA of $600M $1B across DLBCL and indolent lymphomas.
• A cash runway is expected into 2028, providing financial stability for ongoing development and commercialization efforts.
• The PSMA-targeting ADC program is advancing towards IND-enabling activities, representing a promising next-generation candidate.

Negatives

• No explicit negative results or underperformance were detailed in the presentation.

Risks

• The success of the company's strategic restructuring plan is subject to uncertainties.
• Changes in estimated costs associated with the restructuring plan, including workforce reduction and planned closure of the UK facility, could impact financial performance.
• The expected cash runway into 2028 assumes the use of a minimum liquidity amount required under loan agreement covenants.
• Future LOTIS-7 clinical trial results may not be consistent with or different from the presented data, impacting future compendia and regulatory strategy.
• The timing of PFS events for LOTIS-5 and topline publication, as well as the trial results and full FDA approval, are uncertain.
• The company's ability to grow ZYNLONTA revenue in the United States and partners' ability to commercialize ZYNLONTA in foreign markets and obtain regulatory approval are not guaranteed.
• The timing and results of research and development projects or clinical trials, including LOTIS-5, LOTIS-7, and early pre-clinical research for the exatecan-based ADC targeting PSMA, are subject to risks.
• The timing and results of investigator-initiated trials and their potential regulatory and/or compendia strategy and future opportunity are uncertain.
• Actions by the FDA or foreign regulatory authorities could impact product approvals and commercialization.
• Projected peak revenue and expenses are estimates and may not be realized.
• The company's indebtedness, including Healthcare Royalty Management, Blue Owl, and Oaktree facilities, imposes restrictions and requires significant cash to service.
• The ability to comply with the terms of various agreements and repay indebtedness is a risk.
• The company's ability to obtain financial and other resources for its research, development, clinical, and commercial activities is uncertain.
• Uncertainties of international trade policies, including tariffs, sanctions, and trade barriers, could impact business, financial condition, and results of operations.

Future Outlook

The company anticipates significant growth for ZYNLONTA by expanding into earlier lines of therapy and new indications, with key milestones including topline data for LOTIS-5 in 1H 2026, potential confirmatory approval in 2L+ DLBCL by 1H 2027, and pursuing regulatory pathways for indolent lymphomas. They also expect to complete IND-enabling activities for their PSMA-targeting ADC in 1H 2026 and maintain a cash runway into 2028.

Management Comments

• We are delivering on our strategy, supported by an accomplished and multidisciplinary team.
• We believe LOTIS-5 has the potential to be the leading regimen for patients who will not receive complex therapies.
• We believe LOTIS-7 has the potential to be the leading bispecific combination regimen for patients with access to complex therapies.

Industry Context

The announcement highlights ADC Therapeutics' position in the competitive oncology market, particularly in B-cell lymphomas. ZYNLONTA's development in combination with rituximab and bispecific antibodies (like glofitamab) positions it against established and emerging therapies, including CAR T-cell therapies and other bispecifics. The focus on broadly accessible outpatient therapies versus complex inpatient treatments addresses a significant market segment, aiming to capture higher market share by offering competitive efficacy with manageable safety profiles.

Comparison to Industry Standards

• LOTIS-7 (Lonca + Glofit) achieved an 87% Complete Response Rate (CR) in r/r LBCL, which compares favorably to CAR T-cell therapies like Yescarta (axi-cel) at 65% CR and Breyanzi (liso-cel) at 66% CR, and bispecific combinations such as Columvi (glofitamab) + GEMOX at 59% CR.
• LOTIS-5 (Lonca + Rituximab) showed a 50% CR in its safety run-in, which is competitive among broadly accessible therapies like Brentuximab + R2 (45% CR), Polatuzumab + BR (40% CR), and Monjuvi (Tafasitamab + Lenalidomide) (37% CR).
• In r/r MZL, ZYNLONTA's 69.2% CR rate significantly surpasses current FDA-approved/NCCN preferred regimens such as Zanubrutinib (26% CR), Acalabrutinib (13% CR), and Pirtobrutinib (3% CR).
• In r/r FL, ZYNLONTA + Rituximab's 76.9% CR rate is highly competitive, comparing to CAR T-cell therapies like Axi-cel (94% CR) and Liso-cel (97% CR), and exceeding Len + Rituximab (R2) (35% CR) and Benda + Obin (16% CR).

Stakeholder Impact

• Shareholders: Potential for increased shareholder value due to strong clinical data, expanded market opportunities for ZYNLONTA, and a clear development pipeline.
• Patients: New, highly effective, and potentially more accessible treatment options for various types of lymphoma, including difficult-to-treat relapsed/refractory cases.
• Employees: The company's strategic restructuring plan, including workforce reduction and UK facility closure, may impact employees, though it's framed as part of a plan for future growth.
• Healthcare Providers: ZYNLONTA's manageable safety profile and simple Q3W dosing could offer a more accessible treatment option compared to complex inpatient therapies, potentially easing patient management.

Next Steps

• Engage regulatory agencies and evaluate compendia strategies for ZYNLONTA in indolent lymphomas.
• Generate additional data and assess regulatory and compendia strategies for LOTIS-7.
• Share fuller/more mature data for LOTIS-7 in 2H 2025.
• Achieve full enrollment of 100 patients in the recommended dose for LOTIS-7 in 2H 2025.
• Share topline results for LOTIS-5 in 1H 2026.
• Potentially complete IND-enabling activities for the PSMA-targeting ADC in 1H 2026.
• Assess potential partners for the PSMA-targeting ADC.
• Publish and potentially pursue MZL compendia in 2H 2026.
• Seek potential confirmatory approval for LOTIS-5 in 2L+ DLBCL in 1H 2027.
• Publish and potentially pursue LOTIS-5 compendia in 1H 2027.
• Expand the University of Miami IIT for r/r MZL to 50 patients by opening at Emory Winship Cancer Institute and Vanderbilt-Ingram Cancer Center.
• Expand the University of Miami IIT for r/r FL to 100 high-risk r/r FL patients and open at additional US cancer research centers.

Key Dates

Recommendation

The filing presents compelling clinical data for ZYNLONTA across multiple lymphoma indications, demonstrating high complete response rates and durable efficacy that are competitive with or superior to existing therapies, including CAR T-cells and other bispecifics. The clear strategy for market expansion into earlier lines of therapy and new indications, coupled with significant projected peak revenue potential ($600M $1B), indicates strong growth prospects. The expected cash runway into 2028 provides financial stability. While inherent risks in biotech development exist, the robust data and strategic clarity make ADC Therapeutics an attractive investment.

Keywords

ADC Therapeutics, ZYNLONTA, Loncastuximab Tesirine, Antibody-Drug Conjugate, DLBCL, Follicular Lymphoma, Marginal Zone Lymphoma, Lymphoma, Oncology, Biotechnology, Clinical Trials, LOTIS-5, LOTIS-7, PSMA, SEC Filing